Compare stocks

Idorsia Ltd is a biopharmaceutical company headquartered in Allschwil, Switzerland. The company focuses on the discovery, development, and commercialization of innovative medicines. Idorsia’s pipeline includes treatments for a variety of conditions, with a particular emphasis on central nervous system disorders, cardiovascular diseases, and rare diseases. Notably, it was founded in June 2017 as a spinoff from Actelion, following its acquisition by Johnson & Johnson. Idorsia leverages its deep scientific expertise to progress its drug candidates from early-stage research through clinical development, aiming to address significant unmet medical needs. Sources: - Company Website - Publicly available financial and corporate reports

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.